Amra, a Linkoping, Sweden-based digital health company, raised $9m in funding.
The round was co-led by Pfizer Venture Investments and Novo Seeds with participation from Industrifonden.
The company intends to use the funds to establish itself internationally and expand its network amongst researchers and pharmaceutical companies.
Founded in 2010, Amra provides a cloud-based, computer-aided service, AMRA® Profiler, which translates data from a 6-minute whole body MRI scan into fat and muscle measurements in such areas as obesity, NAFLD / NASH, cardiovascular disease, diabetes, oncology, sarcopenia, cachexia, muscle disorders, rare diseases, etc.
The service, which has received CE mark for clinical use in Europe, is moving away from body mass index (BMI) and towards a more precise, individualized Body Composition Profile (BCP) and has the potential to predict the risk of development of diseases such as diabetes, cardiovascular disease, NASH, sarcopenia, and more.
FinSMEs
17/01/2017